Clinical application of ¹⁸F-FDG and ⁶⁸Ga-DOTA-SSA dual-tracer PET/CT in neuroendocrine neoplasms

Compared with conventional CT and MRI imaging examinations, ⁶⁸Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-somatostatin analog (SSA) PET/CT has higher sensitivity and specificity in the diagnosis of neuroendocrine neoplasm (NEN), and it also has important guiding value in the evaluation of curative effect and prognosis. Although not routinely recommended in the diagnosis of NEN, ¹⁸F-fluorodeoxyglucose (FDG) PET/CT can provide complementary information in the differential diagnosis of benign and malignant tumors and the evaluation of prognosis. An overview of the clinical application of ¹⁸F-FDG and ⁶⁸Ga-DOTA-SSA dual-tracer PET/CT in NEN is presented.